

ERRATUM OPEN

Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo

Jason J. Zoeller¹, Roderick T. Bronson², Laura M. Selfors¹, Gordon B. Mills³ and Joan S. Brugge¹ npj Breast Cancer (2017)3:38; doi:10.1038/s41523-017-0031-9

Erratum to: *npj Breast Cancer* (2017); doi:10.1038/s41523-017-0020-z; Published 01 May 2017

Two references were mistakenly omitted from the first sentence of the introduction.

Original text:

Extracellular matrix (ECM) proteins produced by diverse tumor types protect tumor cells from death in response to various agents. 1.2,3,4

- 1. Sethi, T. *et al.* Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. *Nat. Med.* **5**, 662–668 (1999).
- 2. Sherman-Baust, C. A. *et al.* Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. *Cancer Cell* **3**, 377–386 (2003).
- 3. Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S. & Gladson, C. L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. *Clin. Cancer Res.* **5**, 1587–1594 (1999)
- 4. Pupa, S. M. *et al.* Regulation of breast cancer response to chemotherapy by fibulin-1. *Cancer Res.* **67**, 4271–4277 (2007).

Corrected text:

Extracellular matrix (ECM) proteins produced by diverse tumor types protect tumor cells from death in response to various agents. 1,2,3,4,5,6

- 1. Muranen, T. *et al.* Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. *Cancer Cell* **21**, 227–239 (2012).
- 2. Behbod, F. *et al.* An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. *Breast Cancer Res.* **11**, R66 (2009).

- 3. Sethi, T. *et al.* Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. *Nat. Med.* **5**, 662–668 (1999).
- 4. Sherman-Baust, C. A. *et al.* Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. *Cancer Cell* **3**, 377–386 (2003).
- 5. Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S. & Gladson, C. L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. *Clin. Cancer Res.* **5**, 1587–1594 (1999)
- 6. Pupa, S. M. *et al.* Regulation of breast cancer response to chemotherapy by fibulin-1. *Cancer Res.* **67**, 4271–4277 (2007).

All subsequent references have been renumbered accordingly. These errors have now been corrected in the HTML and PDF versions of this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017

¹Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA; ²Rodent Histopathology Core, Harvard Medical School, Boston, MA, USA and ³Systems Biology, UT MD Anderson Cancer Center, Houston, TX, USA Correspondence: Joan S. Brugge (joan_brugge@hms.harvard.edu)





